Huntington Bancshares Incorporated
—Price / book
Market cap
—
Tangible equity
$18.20B
Price / tangible book
—
Price / book
—
Return on equity
9.1%
Return on assets
1.0%
Efficiency ratio
40.2%
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HBAN stock price vs IONS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at IONS's multiple
Needs IONS P/E.
Implied fair value · at HBAN's multiple
Needs Annual EPS is negative, HBAN P/E.
Metric by metric
Price unavailable
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability edge
Asset efficiency edge
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: HBAN FY 2025 (ended Dec 31, 2025) · IONS FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
—
Tangible equity
$18.20B
Price / tangible book
—
Price / book
—
Return on equity
9.1%
Return on assets
1.0%
Efficiency ratio
40.2%
Price / book
Market cap
—
Tangible equity
—
Price / tangible book
—
Price / book
—
Return on equity
-78.0%
Return on assets
-10.8%
Efficiency ratio
—
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Huntington Bancshares Incorporated · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Ionis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.76x
4.59x
Net debt / EBITDA
Leverage against operating earnings
—
1.34x
Cash and equivalents
Liquid reserves on the balance sheet
—
$2.68B
Total debt
Interest-bearing obligations outstanding
$18.48B
$2.24B
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
JPMorgan Chase & Co.
HBAN vs JPM
Bank of America Corporation
HBAN vs BAC
Wells Fargo & Company
HBAN vs WFC
Citigroup Inc.
HBAN vs C
PNC FINANCIAL SERVICES GROUP, INC.
HBAN vs PNC
Sarepta Therapeutics, Inc.
HBAN vs SRPT
Moderna, Inc.
HBAN vs MRNA
Natera, Inc.
HBAN vs NTRA
ILLUMINA, INC.
HBAN vs ILMN
AMGEN INC
HBAN vs AMGN
VERTEX PHARMACEUTICALS INC / MA
HBAN vs VRTX
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.